Alnylam Pharmaceuticals clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
7 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 7 with minor changes only.
- Minor: Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial sites expanded: 10 → 20 locations
- Minor: TRITON-CM · Nucresiran · Transthyretin Amyloidosis With Cardiomyopathy Enrollment increased: 1750 → 2250 participants
- Minor: ALN-4324 on Insulin Sensitivity · Type 2 Diabetes Mellitus Enrollment closed, study ongoing
- Minor: HMBeacon · ALN-6400 in Adult and Adolescent Female · VWD and HMB Trial sites expanded: 21 → 29 locations
- Minor: ZENITH · Zilebesiran · Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Trial sites expanded: 1190 → 1226 locations
- Minor: HELIOS-B · Vutrisiran · Transthyretin Amyloidosis With Cardiomyopathy Study completion pushed from Dec 2, 2026 to Jan 13, 2027
- Minor: ALN-APP · EOAD Primary and study completion moved earlier from Apr 20, 2029 to Jan 11, 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 7 | |
| Phase 1/2 | 3 | |
| Phase 2 | 5 | |
| Phase 3 | 5 |
Not charted: 6 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials
Amyloidosis (9) · Heart Disease (5) · Dementia (4) · Alzheimer's Disease (3) · Obesity (3) · Diabetes (2) · Hypertension (2) · Type 2 Diabetes (2) · Huntington's Disease (1) · Liver Cancer (1)
Get alerts when Alnylam Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.